[8], and pancreatic
[9] cancer. Several studies have demonstrated that increased
CD44 expression activates several signalling pathways related
to cancer progression and metastasis, including Shh pathway
[10]. Song et al. [10] demonstrated that the Shh pathway is
essential for maintenance of human gastric cancer CSCs in
vitro. However, the clinical impact and interaction between
the Shh pathway and CD44 expression in gastric cancer
patients are still uncertain. Here, we aimed to find out
the correlations between CD44, Gli1, and Shh expression
and clinicopathological features, long-term survival, and
recurrence